诺沃库尔
NVCR
14.07
-0.34
-2.36%
诺沃库尔
US · NVCR
#2889 按市值排名
上市于 2015
14.07
-0.34
-2.36%
实时 - 追踪5344个代码 - 心跳于11秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
减持
- 最近一期（2026/Q3）披露持股的机构数量减少了1家。
- 机构持股总比例下降了0.7个百分点。
机构持股
- 机构持股比例
- 90.76% -0.73pp
- 机构数量
- 267 -1
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向分歧机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流入——两者方向出现分歧。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund60.79%
Hedge Fund16.44%
Public Company9.31%
Individual/Insider8.68%
Private Company1.73%
Government Pension Fund1.53%
Insurance Company0.75%
VC/PE Fund0.12%
Other0.56%
主要股东 截至 2026-06-30
FMR
14.92% · 17.37M 股
BlackRock
11.52% · 13.41M 股
Soleus Capital Management, L.P.
8.51% · 9.91M 股
Hansjoerg Wyss
6.99% · 8.14M 股
Vanguard Portfolio Management, LLC
5.39% · 6.27M 股
Vanguard Capital Management, LLC
4.86% · 5.66M 股
Morgan Stanley
3.81% · 4.43M 股
State Street Global Advisors
2.46% · 2.87M 股
Geode Capital Management, LLC
2.40% · 2.80M 股
Wells Fargo & Company
2.17% · 2.53M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 34次买入 · 16次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Hansjoerg Wyss | Former Director | 6.99% |
| William Doyle | Executive Chairperson | 0.46% |
| Asaf Danziger | Chief Executive Officer | 0.19% |
| William Vernon | Lead Independent Director | 0.17% |
| Uri Weinberg | Chief Innovation Officer | 0.13% |
| Frank Leonard | President of CNS Cancers U.S. | 0.13% |
| Ashley Cordova | Chief Financial Officer | 0.11% |
| Barak Ben-Arye | General Counsel | 0.11% |
| Michael Puri | Chief Human Resources Officer | 0.08% |
| Kinyip Leung | Independent Director | 0.08% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-06-29 | Asaf Danziger | Chief Executive Officer | Other Acquisition | +268 | $11.15 |
| 2026-06-29 | Frank Leonard | President of CNS Cancers U.S. | Other Acquisition | +1,905 | $11.15 |
| 2026-06-29 | Michael Puri | Chief Human Resources Officer | Other Acquisition | +1,905 | $11.15 |
| 2026-06-29 | Barak Ben-Arye | General Counsel | Other Acquisition | +1,299 | $11.15 |
| 2026-06-03 | Frank Leonard | President of CNS Cancers U.S. | Open Market Disposition | -34,273 | $17.93 |
| 2026-06-02 | Jeryl Hilleman | Independent Director | Other Acquisition | +11,610 | -- |
| 2026-06-02 | Jeryl Hilleman | Independent Director | Other Derivative Acquisition | +16,999 | $16.15 |
| 2026-06-02 | David Hung | Independent Director | Other Acquisition | +11,610 | -- |
| 2026-06-02 | David Hung | Independent Director | Other Derivative Acquisition | +16,999 | $16.15 |
| 2026-06-02 | Timothy Scannell | Independent Director | Other Acquisition | +11,610 | -- |
| 2026-06-02 | Timothy Scannell | Independent Director | Other Derivative Acquisition | +16,999 | $16.15 |
| 2026-06-02 | Kinyip Leung | Independent Director | Other Acquisition | +11,610 | -- |
| 2026-06-02 | Kinyip Leung | Independent Director | Other Derivative Acquisition | +16,999 | $16.15 |
| 2026-06-02 | William Vernon | Lead Independent Director | Other Acquisition | +11,610 | -- |
| 2026-06-02 | William Vernon | Lead Independent Director | Other Derivative Acquisition | +16,999 | $16.15 |
| 2026-06-02 | Martin Madden | Independent Director | Other Acquisition | +11,610 | -- |
| 2026-06-02 | Martin Madden | Independent Director | Other Derivative Acquisition | +16,999 | $16.15 |
| 2026-06-02 | Kristin Stafford | Independent Director | Other Acquisition | +11,610 | -- |
| 2026-06-02 | Kristin Stafford | Independent Director | Other Derivative Acquisition | +16,999 | $16.15 |
| 2026-06-02 | Allyson Ocean | Independent Director | Other Acquisition | +11,610 | -- |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
诺沃库尔 讨论区 0 条评论